Source:
European Commission, DG Research
| home | lswn | team | privacy | contatti | impressum |
JPMed
Le Scienze Web News
| Files Cards | * | English
[16/12/2009] The Company's proprietary platform technologies overcome major technological and economic obstacles for the development of a new generation of multi-functional, efficacious, safe and standardized botanical therapeutics. The Company focuses its development and commercialization activities on unmet needs in four key target markets: JPMed has developed an alcohol-free unique vehicle for eardrops, comprising OGE (Oil-in-Glycerin Emulsion) which is solely made of permitted for human use pharmaceutical excipients and combination of therapeutic anti-bacterial, anti-fungal and anti-viral mixture of Essential oils. Testimonial results of more than 20 patients revealed that pains are killed in 1-2 hours as compared to 12-24 hours with existing ear drops products. Moreover, within 24-48 hours the ear is free of inflammation. A double blinded human clinical study is ongoing in one of the medical centers in Israel. Aphta Gel(tm) CanKer Sores Treatment Launch in Israel is planned for the 3rd quarter of this year. Based on future available resources, the company plans to pursue registration of this product in the USA as a botanical drug. For mor details, please contact the company, business reference:Medicphar-J3E-mail: info [AT] medicphar.biz |
European Guide Science MuseumsR&D Research and DevelopmentMedilit http://rd.lswn.it is a new Italian joint venture partnership created with the primary aim of providing an important reference point for the collection and placement of existing patents, projects and innovative technologies from Italy and abroad. LSWN.eu Highlighted EventsMetafora
LSWN.eu SocialLogin utente |
|
|